How many insider trades does FilingIQ track for VXRT?

FilingIQ tracks 259 Form 4 insider transactions for VXRT (Vaxart, Inc.), covering filings from Feb 13, 2018 onwards. 20 of those were filed in the last 90 days.

Are VXRT insiders net buyers or net sellers?

Across the full Form 4 history for VXRT, 46 transactions (18%) were open-market purchases and 63 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VXRT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VXRT in?

Vaxart, Inc. (VXRT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.

VXRT insider trading

NasdaqGS Healthcare

Vaxart, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

259

Last 90 days

Buys / sells

18% / 24%

Market cap

$368.37M

About Vaxart, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company website: ateapharma.com

VXRT insider activity at a glance

FilingIQ has scored 259 insider transactions for VXRT since Feb 13, 2018. The most recent filing in our index is dated Mar 28, 2026.

Across the full history, 46 open-market purchases and 63 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VXRT insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VXRT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for VXRT?: FilingIQ tracks 259 Form 4 insider transactions for VXRT (Vaxart, Inc.), covering filings from Feb 13, 2018 onwards. 20 of those were filed in the last 90 days.
Are VXRT insiders net buyers or net sellers?: Across the full Form 4 history for VXRT, 46 transactions (18%) were open-market purchases and 63 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VXRT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VXRT in?: Vaxart, Inc. (VXRT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.

Methodology & sources

Every VXRT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.